Company / Net Income
Protalix BioTherapeutics, Inc. Net Income History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
$8.3M
FY2025
5-year range
-$27.6M / $8.3M
FY2021-FY2025
Trend
+155.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income has fluctuated over the past 10 years, ranging from -$83M in FY2019 to $58M in FY2017.
Based on SEC 10-K filings.
$8M in FY2025.
Improved from -$28M to $8M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, net income increased 155.7% year-over-year.
- Peak net income was recorded in FY2017.
- Lowest net income in the period was in FY2019.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.3M | +155.7% |
| FY2024 | -$14.9M | +45.9% |
| FY2023 | -$27.6M | -322.8% |
| FY2022 | -$6.5M | +64.3% |
| FY2021 | -$18.3M | +30.9% |
| FY2020 | -$26.5M | +68.3% |
| FY2019 | -$83.4M | -243.8% |
| FY2017 | $58.0M | +293.8% |
| FY2016 | -$29.9M | -7.7% |
| FY2015 | -$27.8M | -139.2% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026